Mechanism of Qiguiyin Decoction Sensitizing Levofloxacin Against Multidrug-Resistant Pseudomonas aeruginosa Infection Based on PK-PD and Antibody Chip Technology
Yanling Li,Li Ji,Tian Liu,Guang Xu,Kaihe Wang,Leixin Mu,Yuying Guo,Qun Ma
DOI: https://doi.org/10.2147/idr.s455114
2024-05-28
Infection and Drug Resistance
Abstract:Yanling Li, &ast Li Ji, &ast Tian Liu, Guang Xu, Kaihe Wang, Leixin Mu, Yuying Guo, Qun Ma School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qun Ma, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488, People's Republic of China, Email Background: Qiguiyin decoction (QGYD) is a traditional Chinese medicine (TCM) and its combined application with levofloxacin (LVFX) has been confirmed effective in the clinical treatment of multidrug-resistant Pseudomonas aeruginosa (MDR PA) infection. This study investigated the therapeutic effect and possible mechanism of QGYD in sensitizing LVFX against MDR PA infection. Materials and Methods: Pulmonary infections were induced in rats by MDR PA. The changes in pharmacokinetics-pharmacodynamics (PK-PD) parameters of LVFX after combined with QGYD were investigated in MDR PA-induced rats. Subsequently, the correlation between PK and PD was analyzed and PK-PD models were established to elucidate the relationship between QGYD-induced alterations in LVFX metabolism and its sensitization to LVFX. Antibody chip technology was used to detect the levels of inflammatory factors, suggesting the relationship between the beneficial effect of immune regulation and the sensitization of QGYD. Results: QGYD significantly enhanced the therapeutic efficacy of LVFX against MDR PA infection. The combination of QGYD changed the PK parameters of LVFX such as T max , t 1/2 , MRT, V d /F, CL/F and PD parameters such as MIC, AUC 0-24h /MIC. Predicted results from PK-PD models demonstrated that the antibacterial effect of LVFX was significantly enhanced with the combination of QGYD, consistent with experimental findings. Antibody chip results revealed that the combination of QGYD made IL-1 β, IL-6, TNF- α, IL-10, and MCP-1 levels more akin to those of the blank group. Conclusion: These findings indicated that QGYD could change the PK-PD behaviors of LVFX and help the body restore immune balance faster. This implied that a potential drug interaction might occur between QGYD and LVFX, leading to improved clinical efficacy when combined. Keywords: multidrug-resistant Pseudomonas aeruginosa infection, combination therapy, PK/PD model, Qiguiyin decoction, levofloxacin The overuse of levofloxacin (LVFX) has resulted in a shift in the susceptibility of Pseudomonas aeruginosa (PA) to LVFX, contributing to the rise of multidrug-resistant (MDR) PA strains, posing a significant threat to patient health. 1–4 Guo 5 analyzed drug sensitivity data from pulmonary tuberculosis patients with PA infection between 2016 to 2020, revealing a notable increase in PA resistance to LVFX in 2020. This underscores the challenge of achieving optimal efficacy with LVFX monotherapy, prompting the adoption of combination therapy strategies for the treatment of MDR PA infections. 6 Traditional Chinese medicine (TCM) has played an important role in preventing and treating infected diseases since ancient times. 7 In the clinical treatment of MDR PA infection, numerous Chinese medicinal treatments, along with their concurrent use with antibacterial drugs, have demonstrated efficacy. 8,9 Qiguiyin decoction (QGYD) has a good anti-infection effect combined with antibacterial drugs in clinical practice, 10 which consists of five Chinese medicines including Astragalus membranaceus (Fisch.) Bge, Lonicera japonica Thunb., Angelica sinensis (Oliv.) Diels, Artemisia annua L., and Polygonum cuspidatum Sieb. et Zucc. Our previous studies have shown that QGYD could delay or reverse PA resistance to antibacterial drugs, regulate inflammation and immune dysregulation resulting from PA infection, and enhance therapeutic outcomes when combined with LVFX. 11,12 Nonetheless, the impact of QGYD on the pharmacokinetic-pharmacodynamic (PK-PD) profile of LVFX in PA-infected rats, as well as the mechanism underlying QGYD's sensitization of LVFX, remains obscure. Following PA infection, the body often experiences a disruption in inflammatory factors. MDR PA infections are more prone to inducing or exacerbating inflammatory immune imbalances compared to typical bacterial infections. 13 Some studies have shown that TCM can improve the body's immunity. 14 Consequently, we hypothesize that the co-administration of QGYD influences the PK-PD parameters of LVFX and immune alterations in vivo, thereby facilitating the sensitization of LVFX against MDR PA. We undertook three ma -Abstract Truncated-
pharmacology & pharmacy,infectious diseases